New Weight-Loss drug GZR18 takes on wegovy in major trial

NCT ID NCT07150975

Recruiting now Disease control Sponsor: Gan & Lee Pharmaceuticals. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This Phase 3 trial compares a new injectable drug, GZR18, to the popular weight-loss medication Wegovy (semaglutide) in 420 adults who are obese or overweight. The main goal is to see how much weight participants lose after 52 weeks of treatment. Researchers will also check for side effects and other health benefits.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GZR18 injection
What this could lead to: If GZR18 works better than Wegovy, it could offer a new, more effective weight-loss option for people with obesity or overweight.
What could go wrong: This is an early Phase 3 trial, so results may not confirm superiority. Side effects similar to Wegovy (e.g., nausea, vomiting) are possible, and long-term safety is unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY/OVERWEIGHT IN ADULT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY/OVERWEIGHT IN ADULT

Contacts and locations

Locations

Beijing
RECRUITING

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.